NCT06781125 2025-01-17
One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors
Immorna Biotherapeutics, Inc.
Phase 1 Not yet recruiting
Immorna Biotherapeutics, Inc.
The First Affiliated Hospital of Guangzhou Medical University
Chinese PLA General Hospital
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Changchun GeneScience Pharmaceutical Co., Ltd.
Sanofi
Tianjin Medical University Cancer Institute and Hospital
AstraZeneca